{
    "clinical_study": {
        "@rank": "63785", 
        "arm_group": [
            {
                "arm_group_label": "Transcranial bright light exposure", 
                "arm_group_type": "Experimental", 
                "description": "Transcranially administered bright light exposure for 12 minutes"
            }, 
            {
                "arm_group_label": "Transcranial sham exposure", 
                "arm_group_type": "Sham Comparator", 
                "description": "Transcranially administered sham exposure for 12 minutes"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if transcranially administered bright light has\n      acute effect on anxiety symptoms."
        }, 
        "brief_title": "The Effect of Acute Transcranial Bright Light on Anxiety Symptoms", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Anxiety", 
        "condition_browse": {
            "mesh_term": "Anxiety Disorders"
        }, 
        "detailed_description": {
            "textblock": "Subjects (n=30) with anxiety symptoms will be recruited into the study. To be included into\n      the study, subjects have to get at least seven points in BAI(Becks Anxiety Inventory). At\n      the beginning of the study subject will be randomly assigned to 12 minutes of acute\n      transcranial bright light or placebo exposure group. Anxiety symptoms will be measured using\n      Spielberger State-Trait Anxiety Inventory (STAI, form Y1)self-rating questionnaire just\n      before and 10 and 110 minutes after the experiment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject can read and understand the study protocol\n\n          -  The written informed consent is obtained from subject\n\n          -  Subject's BAI total score >= 7\n\n        Exclusion Criteria:\n\n          -  Subject has a lifetime psychotic disorder\n\n          -  Subject abuses substance or has a dependence\n\n          -  Subject has had suicidal idealization during the past month\n\n          -  Subject use psychotropic medications\n\n          -  Subject has unstable somatic disease\n\n          -  Subject has used bright-light therapy for the current episode\n\n          -  Subject is pregnant\n\n          -  Subject is a relative of a member of research team\n\n          -  Subject has used transcranial light treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938937", 
            "org_study_id": "ANX-a"
        }, 
        "intervention": [
            {
                "arm_group_label": "Transcranial bright light exposure", 
                "intervention_name": "Transcranial bright light device", 
                "intervention_type": "Device", 
                "other_name": "Valkee npt 1100"
            }, 
            {
                "arm_group_label": "Transcranial sham exposure", 
                "intervention_name": "Transcranial sham device", 
                "intervention_type": "Device", 
                "other_name": "Valkee npt 1100"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oulu", 
                    "country": "Finland", 
                    "zip": "90014"
                }, 
                "name": "Oulu University"
            }
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Acute Transcranial Bright Light on Anxiety Symptoms", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Finland: Valvira - National Supervisory Authority for Welfare and Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "STAI-Y1 (Spielberger State-Trait Anxiety Inventory, form Y1)", 
            "measure": "Change in total score of STAI-Y1", 
            "safety_issue": "No", 
            "time_frame": "just before exposure, 10 minutes and 110 minutes after the exposure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938937"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Oulu", 
            "investigator_full_name": "Heidi Jurvelin", 
            "investigator_title": "PhD student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Oulu", 
        "sponsors": {
            "collaborator": {
                "agency": "Valkee Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Oulu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}